These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 12781332

  • 1. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
    Delahoussaye YM, Hay MP, Pruijn FB, Denny WA, Brown JM.
    Biochem Pharmacol; 2003 Jun 01; 65(11):1807-15. PubMed ID: 12781332
    [Abstract] [Full Text] [Related]

  • 2. Tirapazamine: a hypoxia-activated topoisomerase II poison.
    Peters KB, Brown JM.
    Cancer Res; 2002 Sep 15; 62(18):5248-53. PubMed ID: 12234992
    [Abstract] [Full Text] [Related]

  • 3. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes.
    Evans JW, Yudoh K, Delahoussaye YM, Brown JM.
    Cancer Res; 1998 May 15; 58(10):2098-101. PubMed ID: 9605751
    [Abstract] [Full Text] [Related]

  • 4. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
    Hay MP, Pruijn FB, Gamage SA, Liyanage HD, Kovacs MS, Patterson AV, Wilson WR, Brown JM, Denny WA.
    J Med Chem; 2004 Jan 15; 47(2):475-88. PubMed ID: 14711317
    [Abstract] [Full Text] [Related]

  • 5. Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
    Guise CP, Abbattista MR, Anderson RF, Li D, Taghipouran R, Tsai A, Lee SJ, Smaill JB, Denny WA, Hay MP, Wilson WR, Hicks KO, Patterson AV.
    Molecules; 2020 Oct 22; 25(21):. PubMed ID: 33105798
    [Abstract] [Full Text] [Related]

  • 6. Enhanced conversion of DNA radical damage to double strand breaks by 1,2,4-benzotriazine 1,4-dioxides linked to a DNA binder compared to tirapazamine.
    Anderson RF, Harris TA, Hay MP, Denny WA.
    Chem Res Toxicol; 2003 Nov 22; 16(11):1477-83. PubMed ID: 14615975
    [Abstract] [Full Text] [Related]

  • 7. Photodynamic Therapy with Liposomal Zinc Phthalocyanine and Tirapazamine Increases Tumor Cell Death via DNA Damage.
    Broekgaarden M, Weijer R, van Wijk AC, Cox RC, Egmond MR, Hoebe R, van Gulik TM, Heger M.
    J Biomed Nanotechnol; 2017 Feb 22; 13(2):204-20. PubMed ID: 29377650
    [Abstract] [Full Text] [Related]

  • 8. Metabolism of tirapazamine by multiple reductases in the nucleus.
    Delahoussaye YM, Evans JW, Brown JM.
    Biochem Pharmacol; 2001 Nov 01; 62(9):1201-9. PubMed ID: 11705453
    [Abstract] [Full Text] [Related]

  • 9. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
    Hicks KO, Siim BG, Pruijn FB, Wilson WR.
    Radiat Res; 2004 Jun 01; 161(6):656-66. PubMed ID: 15161354
    [Abstract] [Full Text] [Related]

  • 10. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.
    Cancer Res; 2004 Jan 15; 64(2):736-42. PubMed ID: 14744792
    [Abstract] [Full Text] [Related]

  • 11. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH, Siim BG, Evans JW, Brown JM.
    Biochem Pharmacol; 1997 Jul 15; 54(2):249-57. PubMed ID: 9271329
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
    Hicks KO, Siim BG, Jaiswal JK, Pruijn FB, Fraser AM, Patel R, Hogg A, Liyanage HD, Dorie MJ, Brown JM, Denny WA, Hay MP, Wilson WR.
    Clin Cancer Res; 2010 Oct 15; 16(20):4946-57. PubMed ID: 20732963
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of DNA replication by tirapazamine.
    Peters KB, Wang H, Brown JM, Iliakis G.
    Cancer Res; 2001 Jul 15; 61(14):5425-31. PubMed ID: 11454687
    [Abstract] [Full Text] [Related]

  • 14. Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine.
    Shin HJ, Kim JY, Yoo CW, Roberts SA, Lee S, Choi SJ, Lee HY, Lee DH, Kim TH, Cho KH.
    J Cancer Res Clin Oncol; 2008 Mar 15; 134(3):397-404. PubMed ID: 17724612
    [Abstract] [Full Text] [Related]

  • 15. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
    Dorie MJ, Kovacs MS, Gabalski EC, Adam M, Le QT, Bloch DA, Pinto HA, Terris DJ, Brown JM.
    Neoplasia; 1999 Nov 15; 1(5):461-7. PubMed ID: 10933062
    [Abstract] [Full Text] [Related]

  • 16. DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2).
    Chowdhury G, Junnotula V, Daniels JS, Greenberg MM, Gates KS.
    J Am Chem Soc; 2007 Oct 24; 129(42):12870-7. PubMed ID: 17900117
    [Abstract] [Full Text] [Related]

  • 17. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
    Xu P, Huang JM, Ren Y, Zha X, Deng BF, Wu JH, Lang JY.
    Chin J Cancer; 2010 Feb 24; 29(2):126-30. PubMed ID: 20109337
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation.
    Hong B, Lui VW, Hui EP, Ng MH, Cheng SH, Sung FL, Tsang CM, Tsao SW, Chan AT.
    Invest New Drugs; 2011 Jun 24; 29(3):401-10. PubMed ID: 20013349
    [Abstract] [Full Text] [Related]

  • 19. Suppression of hypoxia-inducible factor 1α (HIF-1α) by tirapazamine is dependent on eIF2α phosphorylation rather than the mTORC1/4E-BP1 pathway.
    Zhang J, Cao J, Weng Q, Wu R, Yan Y, Jing H, Zhu H, He Q, Yang B.
    PLoS One; 2010 Nov 09; 5(11):e13910. PubMed ID: 21085474
    [Abstract] [Full Text] [Related]

  • 20. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
    Chinje EC, Cowen RL, Feng J, Sharma SP, Wind NS, Harris AL, Stratford IJ.
    Mol Pharmacol; 2003 Jun 09; 63(6):1248-55. PubMed ID: 12761334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.